The Effect of SGLT2i on the GH/IGF1 Axis in Newly Diagnosed Male T2D Patients - a Prospective, Randomized Case-control Study

Overview

Journal Endocrine

Specialty Endocrinology

Date 2024 Jan 3

PMID 38168834

Authors

Jing Lin

Liqin Zhan

Zheng Chen

Xiaying Lin

Rongfeng Zhu

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the effect of SGLT2i on the GH/IGF1 axis in male patients with newly diagnosed type 2 diabetes (T2D).

Methods: Sixty male patients with newly diagnosed T2D were recruited, and randomly assigned to Metformin+SGLT2i group or Metformin group after baseline assessment. All patients received standard lifestyle interventions, and blood indices were obtained before and after 12 weeks of treatment.

Results: After 12 weeks of treatment with Metformin+SGLT2i, there were noteworthy improvements in patients' FPG (Fasting plasma glucose), HBA1c, HOMA-IR, HOMA-β, TyG (Triglyceride-glucose) index and UACR (P < 0.05). Both IGF1 (P = 0.01) and the IGF1/IGFBP3 ratio (P < 0.01) considerably increased, while GH and IGFBP3 did not show significant changes. When comparing Metformin+SGLT2i group to Metformin group, SGLT2i significantly improved HOMA-IR [P = 0.04], and elevated IGF1/IGFBP3 ratio [P = 0.04], SGLT2i showed a tendency of increasing IGF1 (P = 0.10), but this was not statistically meaningful. There was no effect on GH and IGFBP3. Correlation analysis showed that blood IGF1 was negatively correlated with FPG, HBA1c, HOMA-IR, TyG index and positively correlated with IGFBP3. Regression analysis indicated that FPG and testosterone had a negative effect on blood IGF1 level, while HOMA-IR had no obvious effect.

Conclusion: In male patients with newly diagnosed T2D, SGLT2i can increase IGF1/IGFBP3 ratio, alleviate insulin resistance, but has no significant effect on GH and IGF1 levels. Additionally, our study showed that Metformin+SGLT2i treatment resulted in an increase in blood IGF1 levels and improved insulin resistance, suggesting a potentially beneficial role of IGF1 in newly diagnosed T2D.

Citing Articles

Influence of sodium-glucose cotransporter 2 inhibitors on the triglyceride-glucose index in acute myocardial infarction patients with type 2 diabetes mellitus.

Wang K, Fan T, He F, Li H, Fang Y, Hu G Cardiovasc Diagn Ther. 2025; 14(6):1096-1107.

PMID: 39790202 PMC: 11707467. DOI: 10.21037/cdt-24-287.

References

Perry R, Shulman G . Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020; 295(42):14379-14390. PMC: 7573269. DOI: 10.1074/jbc.REV120.008387. View

Packer M, Anker S, Butler J, Filippatos G, Pocock S, Carson P . Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383(15):1413-1424. DOI: 10.1056/NEJMoa2022190. View

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

Baxter R . IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer. 2014; 14(5):329-41. DOI: 10.1038/nrc3720. View

Yakar S, Liu J, STANNARD B, Butler A, Accili D, Sauer B . Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci U S A. 1999; 96(13):7324-9. PMC: 22084. DOI: 10.1073/pnas.96.13.7324. View

Miyamoto S, Nakamura M, Yano K, Ishii G, Hasebe T, Endoh Y . Matrix metalloproteinase-7 triggers the matricrine action of insulin-like growth factor-II via proteinase activity on insulin-like growth factor binding protein 2 in the extracellular matrix. Cancer Sci. 2007; 98(5):685-91. PMC: 11158237. DOI: 10.1111/j.1349-7006.2007.00448.x. View

Foulstone E, Prince S, Zaccheo O, Burns J, Harper J, Jacobs C . Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol. 2005; 205(2):145-53. DOI: 10.1002/path.1712. View

Firth S, Baxter R . Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002; 23(6):824-54. DOI: 10.1210/er.2001-0033. View

Sesti G, Sciacqua A, Cardellini M, Marini M, Maio R, Vatrano M . Plasma concentration of IGF-I is independently associated with insulin sensitivity in subjects with different degrees of glucose tolerance. Diabetes Care. 2004; 28(1):120-5. DOI: 10.2337/diacare.28.1.120. View

10.

Lewitt M, Hilding A, Brismar K, Efendic S, Ostenson C, Hall K . IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women. Eur J Endocrinol. 2010; 163(2):233-42. PMC: 2909736. DOI: 10.1530/EJE-10-0301. View

11.

Wallander M, Brismar K, Ohrvik J, Ryden L, Norhammar A . Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction. Diabetologia. 2006; 49(10):2247-55. DOI: 10.1007/s00125-006-0386-1. View

12.

Sandhu M, Heald A, Gibson J, Cruickshank J, Dunger D, Wareham N . Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet. 2002; 359(9319):1740-5. DOI: 10.1016/S0140-6736(02)08655-5. View

13.

Petersson U, Ostgren C, Brudin L, Brismar K, Nilsson P . Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): the Söderåkra Cardiovascular Risk Factor Study. Diabetes Metab. 2009; 35(3):198-205. DOI: 10.1016/j.diabet.2008.11.003. View

14.

Lewitt M, Hilding A, Ostenson C, Efendic S, Brismar K, Hall K . Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia. 2008; 51(7):1135-45. DOI: 10.1007/s00125-008-1016-x. View

15.

Levy J, Matthews D, Hermans M . Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998; 21(12):2191-2. DOI: 10.2337/diacare.21.12.2191. View

16.

Xu L, Wu M, Chen S, Yang Y, Wang Y, Wu S . Triglyceride-glucose index associates with incident heart failure: A cohort study. Diabetes Metab. 2022; 48(6):101365. DOI: 10.1016/j.diabet.2022.101365. View

17.

Srinivasan S, Singh P, Kulothungan V, Sharma T, Raman R . Relationship between triglyceride glucose index, retinopathy and nephropathy in Type 2 diabetes. Endocrinol Diabetes Metab. 2021; 4(1):e00151. PMC: 7831221. DOI: 10.1002/edm2.151. View

18.

Qin Z, Zhao J, Geng J, Chang K, Liao R, Su B . Higher Triglyceride-Glucose Index Is Associated With Increased Likelihood of Kidney Stones. Front Endocrinol (Lausanne). 2021; 12:774567. PMC: 8667164. DOI: 10.3389/fendo.2021.774567. View

19.

Granata R . Peripheral activities of growth hormone-releasing hormone. J Endocrinol Invest. 2016; 39(7):721-7. DOI: 10.1007/s40618-016-0440-x. View

20.

Gardner E, Kentistou K, Stankovic S, Lockhart S, Wheeler E, Day F . Damaging missense variants in implicate a role for IGF-1 resistance in the etiology of type 2 diabetes. Cell Genom. 2022; 2(12):None. PMC: 9750938. DOI: 10.1016/j.xgen.2022.100208. View